23:12 , Jun 11, 2018 |  BC Extra  |  Preclinical News

Summit identifies two new classes of antibiotics

Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) identified two new types of narrow-spectrum antibiotics targeting new Neisseria gonorrhoeae targets that could help treat gonorrhea. Summit presented its findings at the American Society for Microbiology Microbe (ASM Microbe)...
19:12 , Jun 14, 2017 |  BC Innovations  |  Translation in Brief

Connecting microbiome dots

Although bacteriophages are viruses that infect bacteria, new work from the Human Microbiology Institute suggests bacteriophages may also underly a variety of human diseases by infecting the gut microbiome. At this month’s American Society for...
07:00 , Aug 22, 2016 |  BioCentury  |  Emerging Company Profile

Metal smithing

Forge Therapeutics Inc. is using a library of metal-binding pharmacophores that avoid known pharmacologic and safety liabilities of a common metal-binding motif to create inhibitors of metalloenzymes, starting with notoriously tough targets. Forge's lead program...
07:00 , Jul 18, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Depression Sphingomyelin phosphodiesterase 1 acid lysosomal (SMPD1; ASM) Mouse and cell culture studies suggest inhibiting SMPD1 could be useful for treating...
07:00 , Jul 18, 2013 |  BC Innovations  |  Targets & Mechanisms

Depressing sphingolipids

European researchers have obtained the most compelling evidence yet that targeting sphingolipid metabolism could help treat depression. 1 The team has shown that two known antidepressants inhibit sphingolipid metabolism and now is planning to screen...
00:14 , May 15, 2012 |  BC Extra  |  Company News

F-star names Haurum CEO, Dancer COO

Antibody company F-star Biotechnologische Forschungs und Entwicklungs GmbH (Vienna, Austria) hired John Haurum as CEO. Haurum is the former VP of research at ImClone Systems Inc. , which Eli Lilly and Co. (NYSE:LLY) acquired 2008....
07:00 , Apr 30, 2012 |  BC Week In Review  |  Clinical News

Oforta fludarabine regulatory update

FDA Commissioner Margaret Hamburg revoked accelerated approval of Oforta fludarabine from Sanofi as a second-line therapy to treat B cell chronic lymphocytic leukemia. According to the agency, Sanofi asked FDA to withdraw approval of Oforta,...
01:04 , Apr 26, 2012 |  BC Extra  |  Company News

FDA pulls Oforta approval

FDA Commissioner Margaret Hamburg revoked accelerated approval of Oforta fludarabine from Sanofi (Euronext:SAN; NYSE:SNY) as a second-line therapy to treat B cell chronic lymphocytic leukemia. According to the agency, Sanofi asked FDA to withdraw approval...
00:35 , Nov 24, 2011 |  BC Extra  |  Politics & Policy

BIA's Gaymond departing as CEO

The U.K. BioIndustry Association said CEO Nigel Gaymond left to pursue other opportunities. Glyn Edwards will become interim CEO. Edwards was CEO of cancer company Antisoma plc (LSE:ASM)....
07:00 , May 30, 2011 |  BioCentury  |  Finance

Europe's Iceberg 2011: A rising tide; demand to match

Europe's biotech industry is maturing, as a handful of public companies are transitioning from sizable cash burners to commercial enterprises, while the number of private clinical-stage companies has reached record levels. Indeed, BioCentury's 9th Annual...